Arbuthnot Banking Group: Back to profitable growth with interest-rate kicker

Hardman & Co
[shareaholic app="share_buttons" id_name="post_below_content"]

The key message from the 2021 results is that Arbuthnot Banking Group plc (LON:ARBB) is back to profitable growth with an interest-rate-upside kicker. End-2021 assets were at the levels management had forecast for that date, prior to the pandemic. In contrast, today’s share price is 965p, against 1,350p in January 2020. The accounts were complicated by a number of exceptional items, but, adjusting for them on our basis, underlying profit was £3.4m. Giving credit for more normal interest rates and a one-off fraud, they were £17m. Looking forward, franchise growth is key: loans up 25% (underlying 29%), deposits 20%, and AUM 18%. The allocation of capital to high-margin, specialist SME finance continues.

  • Sensitivity to rising rates: Arbuthnot Banking Group is a beneficiary of rising interest rates (£11.5m profit p.a. if base rate is 75bp not 10bp). The pain from impairments is not expected to become a material factor until base rates go above 2%, so, for the near future, accelerating expectations of rate increases provides a material upside.
  • Results in more detail: Profit before tax was £4.6m (2020: loss £1.1m). Group operating income rose to £88.7m (2020: £72.5m). Earnings per share were 45.2p (2020: negative 8.9p). Final dividend declared 22p (2020: nil). Net assets p/share were 1,315p (2020: 1,270p). Total capital ratio was 14.9% (2020: 18.7%).
  • Valuation: Our multiple approaches see a broad range of valuations: £11.51 Dividend Discount Model (DDM), £16.85 SOTP and £18.41 Gordon Growth Model (GGM). The average is £15.59 is, up from £13.83, reflecting earnings upgrades and the move to a new base year for a growth business. Trading at 74% of NAV appears anomalous.
  • Risks: Going forward, the key risk is credit. Historically, ABG has been very conservative in lending criteria and security taken. Its financial strength means that ABG can take time to optimise recoveries. Other risks include reputation, regulation and compliance.
  • Investment summary: Arbuthnot Banking Group offers strong-franchise and continuing-business (normalised) profit growth. Its balance sheet strength gives it a number of wide-ranging options to develop organic and inorganic opportunities. The latter are likely to increase in uncertain times. Management has been innovative, but also very conservative, in managing risk. Having a profitable, well-funded, well-capitalised and strongly growing bank priced below book value is an anomaly.

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

If our articles help you then why not add us as a preferred news source on Google.

Higher bond yields sharpen the focus on AI and asset allocation

Higher bond yields and a shift towards AI software are changing market positioning as investors weigh resilient growth against persistent inflation and debt supply.

Shakespeare Monofilament acquisition secures £5.92m asset-based funding package

Nova Capital Management’s acquisition of Shakespeare Monofilament UK is supported by a £5.92 million asset-based lending package spanning receivables, inventory, machinery and property.

Arbuthnot Latham launches cross-border investment service for US-connected UK clients

Arbuthnot Latham has launched Global Direct Service for US-connected UK clients, adding a direct-investment option to its private banking and wealth management offering.

AI spending comes under pressure as markets demand clearer returns

Markets are shifting their focus from the scale of AI spending to the returns it can generate as interest rates and competition remain key risks.

Arbuthnot Banking Group reports record deposits and wealth assets (LON:ARBB)

Hardman & Co analyst Mark Thomas discusses Arbuthnot Banking Group’s first-half 2026 results, highlighting record client balances, strong growth across deposits, wealth management and specialist lending, and the potential benefit of higher-for-longer interest rates.

Nova Capital backs Shakespeare Monofilament acquisition with £5.92m funding package

Nova Capital’s acquisition gives Shakespeare new ownership and a £5.92 million funding structure designed to support working capital and future development.

Search

Search